CSF sTREM2 is increased in humans with a biomarker profile of AD years before the onset of dementia symptoms (Heslegrave et al, 2016; Piccio et al, 2016; Suarez‐Calvet et al, 2016a,b, 2019), where higher CSF sTREM2 at a given biomarker level of Aβ and pathologic tau was associated with larger gray matter volume (Gispert et al, 2016b) and slower subsequent cognitive and clinical decline in symptomatic elderly participants (Ewers et al, 2019). The gene discussed is MAPT; the disease is Alzheimer disease.